Analyst Ratings For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Today, Credit Suisse Group initiated coverage on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with a Outperform.
There are 7 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Buy with a consensus target price of $8.6667 per share, a potential 229.53% upside.
Some recent analyst ratings include
- 2/15/2019-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has coverage initiated with a Outperform rating
- 12/12/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy rating reiterated by HC Wainwright with a $9.00 price target
- 12/11/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Oppenheimer
- 10/23/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has coverage initiated with a Buy ➝ Buy rating and $9.00 price target
- On 12/14/2018 Raffi Asadorian, CFO, bought 5,000 with an average share price of $2.78 per share and the total transaction amounting to $13,900.00.
- On 12/14/2018 Vincent J Angotti, CEO, bought 3,610 with an average share price of $2.78 per share and the total transaction amounting to $10,035.80.
- On 12/12/2018 Vincent J Angotti, CEO, bought 10,000 with an average share price of $2.99 per share and the total transaction amounting to $29,900.00.
- On 11/19/2018 Pamela P Palmer, Insider, bought 16,000 with an average share price of $3.07 per share and the total transaction amounting to $49,120.00.
- On 11/15/2018 Mark G Edwards, Director, bought 20,700 with an average share price of $2.82 per share and the total transaction amounting to $58,374.00.
- On 11/13/2018 Raffi Asadorian, CFO, bought 5,000 with an average share price of $3.13 per share and the total transaction amounting to $15,650.00.
- On 10/15/2018 Badri N Dasu, Insider, sold 28,351 with an average share price of $5.00 per share and the total transaction amounting to $141,755.00.
About AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Recent Trading Activity for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Shares of AcelRx Pharmaceuticals Inc closed the previous trading session at 2,63 +0,070 2,73 % with 2.53 shares trading hands.